At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed advanced biliary tract cancer (cholangiocarcinoma or gallbladder cancer) with prior progression or intolerance to at least one line of systemic anticancer therapy
- ✓Measurable disease by imaging
- ✓ECOG performance status 0 or 1
- ✓Absolute neutrophil count ≥1500/mm³
- ✕Pregnant or nursing persons
- ✕Immunocompromised state or HIV-positive patients on antiretroviral therapy
- ✕Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness limiting compliance
- ✕Other investigational agent for primary neoplasm within 21 days prior to registration
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 for Cholangiocarcinoma and 6 related conditions. Completed, enrolled 28 participants across 2 sites.
Detailed Summary
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Timeline
Interventions
Correlative studies
Given PO